

Special Issue

Advances in Genetics and Epigenetics of Bladder Cancer

Message from the Guest Editor

The urinary bladder and the upper urothelial tract are locations of multifocal and recurrent urothelial tumors with or without tumor progression. Since 2004, genetic data have been integrated into the WHO classification, while the Cancer Genome Atlas (TCGA) and a plethora of new techniques to assess genetic changes have provided thought-provoking data. Additionally, epigenetic mechanisms, such as DNA methylation, histone modifications, and its crosstalk, also shape the active and inactive states of the blueprint. Thus, both genetics and epigenetics hold clues to identify novel biomarkers for diagnosis, risk stratification or therapeutic approaches and to explain the development of heterogeneous cancer (cell) phenotypes. To provide an overview of recent knowledge, this Special Issue will span various topics ranging from genetic and epigenetic changes in early- (carcinoma in situ) and late-stage muscle-invasive bladder cancers (MIBC) over actionable mutation and genetic alterations, such as biomarkers, to mechanisms of controlling histone modifiers in urothelial tumorigenesis, with special emphasis on prognostic and therapeutic options for individual patients.

Guest Editor

Dr. Michael Rose

Oncological Pathology Group, Institute of Pathology, Hospital of the RWTH Aachen University, Pauwelsstr.30, 52074 Aachen, Germany

Deadline for manuscript submissions

closed (30 April 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/171756

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)